552O FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel

Seligmann, J., Morton, D., Seymour, M. et al. (11 more authors) (2023) 552O FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel. In: Annals of Oncology. ESMO Congress 2023, 2023-10-20 2023-10-24, Madrid, Spain. Elsevier , S412-S412.

Metadata

Authors/Creators:
Dates:
  • Published (online): 20 October 2023
  • Published: 20 October 2023
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Pathology and Data Analytics
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Medical Research (LIMR) > Division of Oncology
Funding Information:
FunderGrant number
Yorkshire Cancer Research Account Ref: 2UOLEEDSL386-RA/2015/R2/003
Cancer Research UK Supplier No: 138573RCCCTF-Nov21\100001
Depositing User: Symplectic Publications
Date Deposited: 20 Dec 2023 10:10
Last Modified: 20 Dec 2023 10:10
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.annonc.2023.09.1743

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)